Clinical Trial Update: An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis [Phase 2]

View source ↗

Summary

Phase 2a open-label trial evaluating GR-MD-02 for safety and efficacy in psoriasis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• GR-MD-02 (GR-MD-02)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2020-09-07